<unk>  refers to<unk>  screening strategies used to identify early<unk><unk> s before they cause symptoms, at a point where they are more likely to be curable.<unk>  is critically important because of the incidence and prevalence of<unk><unk> . More than 235,000 new cases of<unk><unk>  are expected in the United States in 2021 with approximately 130,000 deaths expected in 2021. In addition, at the time of diagnosis, 57% of<unk><unk> s are discovered in advanced stages (III and IV), meaning they are more widespread or aggressive<unk> s. Because there is a substantially higher probability of long-term survival following treatment of localized (60%) versus advanced stage (6%)<unk><unk> ,<unk>  aims to diagnose the disease in the localized (stage I) stage. Results from large randomized studies have recently prompted a large number of professional organizations and governmental agencies in the U.S. to now recommend<unk>  in select populations. The 3 main types of<unk>  are low-dose, computerized tomographic (LDCT) screening, chest x-rays, and sputum cytology tests. Currently multiple professional organizations, as well as the United States Preventive Services Task Force (USPSTF), the Centers for Medicare and Medicaid Services (CMS) and the European Commission's science advisors concur and endorse low-dose, computerized tomographic screening for individuals at high-risk of<unk><unk> .
Lung cancer screening
Breast cancer screening
Prostate cancer screening
Cancer screening
Hypertrophic cardiomyopathy screening
Lung cancer staging
Cardiology diagnostic tests and procedures
Cervical screening